Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

ClinicalTrials.gov ID: NCT05962398

Public ClinicalTrials.gov record NCT05962398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B

Study identification

NCT ID: NCT05962398
Recruitment status: Enrolling by invitation
Study type: Observational
Phase: Not listed
Lead sponsor: CSL Behring; Industry
Enrollment: 56 participants

Conditions and interventions

Conditions

Hemophilia B

Interventions

AAV5-hFIXco-Padua Genetic

Genetic

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 29, 2023
Primary completion: Mar 22, 2035
Completion: Mar 22, 2035
Last update posted: Jul 17, 2025

2023 – 2035

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
10-15 Phoenix Childrens Hospital	Phoenix	Arizona	85016	—
10-14 Arkansas Children's Hospital - Pharmacology	Little Rock	Arkansas	72202	—
10-22 Orthopaedic Institute for Children	Los Angeles	California	90007	—
10-21 Children's Hospital of Los Angeles	Los Angeles	California	90027	—
10-63 UC Davis Medical Center	Sacramento	California	95817	—
10-12 University of California, San Diego (UCSD)	San Diego	California	92121	—
10-25 University of Colorado Denver	Aurora	Colorado	80045	—
10-19 University of South Florida	Tampa	Florida	33612	—
10-10 University of Michigan Medical Center	Ann Arbor	Michigan	48109	—
10-16 University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
10-18 Oregon Health & Science University	Portland	Oregon	97239	—
10-20 Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
10-28 University of Texas Health Science Center	Houston	Texas	77030	—
10-26 University of Utah	Salt Lake City	Utah	84108	—
10-62 Washington Institute for Coagulation	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05962398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 17, 2025 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05962398 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →